<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926965</url>
  </required_header>
  <id_info>
    <org_study_id>TD</org_study_id>
    <secondary_id>TD</secondary_id>
    <nct_id>NCT00926965</nct_id>
  </id_info>
  <brief_title>Tardive Dyskinesia and Cognitive Function</brief_title>
  <acronym>TD</acronym>
  <official_title>Tardive Dyskinesia and Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous researchers indicate that impaired cognitive flexibility was the primary factor
      distinguishing patients with from those without tardive dyskinesia (TD)1, and cognitive
      dysfunction correlates positively with the severity of TD2. Longitudinal data raised the
      possibility that the association between cognitive dysfunction and TD may reflect not organic
      vulnerability to but rather a state marker for this movement disorder as &quot;tardive dementia&quot;3.
      Atypical antipsychotic had been reported to alleviate the severity of TD4 and improved
      neurocognitive function separately5. But no researchers ever investigated the correlation of
      the two effects simultaneously. This randomized, single-blind and controlled study compared
      the effect of atypical antipsychotic on TD, neurocognitive function and associated factors
      for these changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eighty chronic schizophrenia inpatients who received conventional antipsychotics for more
      than one year, and met Schooler and Kane's criteria for persistent TD were enrolled in the
      study. The subjects were randomized to three groups: the olanzapine, amisulpride and FGA
      (first generation antipsychotic) controlled groups. Neurocognitive function were assessed
      using Wisconsin Card Sorting Test (WSCT) and Continuous Performance test (CPT) at baseline,
      12th week and 24th week. Clinical successive ratings were performed with Brief psychiatric
      Rating Scale (BPRS), AIMS (Abnormal Involuntary Movement Rating Scale), Simpson-Angus Rating
      Scale (SAS), Udvalg for Kliniske Undersogelser side effect ratings (UKU) and Barnes akathesia
      scale (BAS).To evaluate the influences of prognostic factors on tardive dyskinesia and
      neurocognitive function and to control for all potential confounding variables, longitudinal
      analyses on the repeated measures data were conducted using generalized estimating equation
      models (GEE).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of Abnormal Involuntary movement scale(AIMS), Wisconsin Card Sorting Test (WSCT) and Continuous Performance test (CPT)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief psychiatric Rating Scale (BPRS), Simpson-Angus Rating Scale (SAS), Udvalg for Kliniske Undersogelser side effect ratings (UKU) and Barnes akathesia scale (BAS).body weight, porlactin, metabolic components</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Tardive Dyskinesia</condition>
  <condition>Neurocognitive Function</condition>
  <arm_group>
    <arm_group_label>Olanzapine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>randomized to Olanzapine group with dose range of 2.5-30mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpiride group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FGA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects were randomized to maintain the conventional antipsychotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amisulpride</intervention_name>
    <description>amisulpride tablet 100-1200mg/day for 24 months</description>
    <arm_group_label>Amisulpiride group</arm_group_label>
    <other_name>solian</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine tablet 2.5 to 30 mg/day for 24 months</description>
    <arm_group_label>Olanzapine group</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional antipsychotics</intervention_name>
    <description>the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics</description>
    <arm_group_label>FGA group</arm_group_label>
    <other_name>conventional antipsychotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  schizophrenia inpatients who received conventional antipsychotics for more than one
             year,

          -  those who met Schooler and Kane's criteria for persistent TD.

        Exclusion Criteria:

          -  mental retardation,

          -  organic mental disorder,

          -  pregnancy and allergy to trial drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya Mei Bai, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yu-Li Veternas Hospital</name>
      <address>
        <city>Hualien</city>
        <zip>981</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>June 23, 2009</last_update_submitted>
  <last_update_submitted_qc>June 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yu-Li Veterans Hospital</name_title>
    <organization>Yu-Li Veterans Hospital</organization>
  </responsible_party>
  <keyword>tardive dyskinesia</keyword>
  <keyword>neurocognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

